Evidence map›Paper›PMID 31447850›Full record

ArticleFrontiers in immunology2019

Have Cells Harboring the HIV Reservoir Been Immunoedited?

Szu-Han Huang, Chase D McCann, Talia M Mota, Chao Wang, Steven M Lipkin, R Brad Jones

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. HIV Nef amplifies mechanical heterogeneity to promote immune evasion.bioRxiv : the preprint server for biology · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Selective BCL-XJournal of virology · 2021
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Szu-Han HuangDepartment of Medicine, Weill Cornell Medical College, New York, NY, United States.
Chase D McCannDepartment of Medicine, Weill Cornell Medical College, New York, NY, United States.
Talia M MotaDepartment of Medicine, Weill Cornell Medical College, New York, NY, United States.
Chao WangDepartment of Medicine, Weill Cornell Medical College, New York, NY, United States.
Steven M LipkinDepartment of Medicine, Weill Cornell Medical College, New York, NY, United States.
R Brad JonesDepartment of Medicine, Weill Cornell Medical College, New York, NY, United States.
Cornell University · US

Funding

BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral EradicationUM1AI126617 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD, NIXON, DOUGLAS F · 2016 to 2020
$28.1M
LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGENSR01CA031798 · NCI · IMMUNE DISEASE INSTITUTE, INC. · PI SPRINGER, TIMOTHY A · 1985 to 2018
$5.1M
Targeted delivery of cytopathicity enhancing agents, and co-ordination with shock and kill, to reduce HIV reservoirsR01AI147845 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI IRVINE, DARRELL J, JONES, R. BRAD · 2019 to 2023
$4.0M
CTL-Mediated Elimination of Replication Competent vs. Defective HIV Proviruses from Natural Latent Reservoirs: Roles of Antigen Specificity and Functional CharacteristicsR01AI131798 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD · 2017 to 2021
$2.1M
NCI NIH HHS L40 CA231425NCI NIH HHS R01 CA031798NIAID NIH HHS R01 AI131798NIAID NIH HHS R01 AI147845NIAID NIH HHS UM1 AI126617
6 · The paper itself

Abstract

Immunoediting is an important concept in oncology, delineating the mechanisms through which tumors are selected for resistance to immune-mediated elimination. The recent emergence of immunotherapies, such as checkpoint inhibitors, as pillars of cancer therapy has intensified interest in immunoediting as a constraint limiting the efficacy of these approaches. Immunoediting manifests at a number of levels for different cancers, for example through the establishment of immunosuppressive microenvironments within solid tumors. Of particular interest to the current review, selection also occurs at the cellular level; and recent studies have revealed novel mechanisms by which tumor cells acquire intrinsic resistance to immune recognition and elimination. While the selection of escape mutations in viral epitopes by HIV-specific T cells, which is a hallmark of chronic HIV infection, can be considered a form of immunoediting, few studies have considered the possibility that HIV-infected cells themselves may parallel tumors in having differential intrinsic susceptibilities to immune-mediated elimination. Such selection, on the level of an infected cell, may not play a significant role in untreated HIV, where infection is propagated by high levels of cell-free virus produced by cells that quickly succumb to viral cytopathicity. However, it may play an unappreciated role in individuals treated with effective antiretroviral therapy where viral replication is abrogated. In this context, an "HIV reservoir" persists, comprising long-lived infected cells which undergo extensive and dynamic clonal expansion. The ability of these cells to persist in infected individuals has generally been attributed to viral latency, thought to render them invisible to immune recognition, and/or to their compartmentalization in anatomical sites that are poorly accessible to immune effectors. Recent data from

Indexed as

Anti-HIV AgentsCD8-Positive T-LymphocytesCytotoxicity, ImmunologicHIV InfectionsHumansNeoplasmsVirus IntegrationVirus LatencyAnti-HIV AgentscancerHIVimmunoeditingimmunotherapylatent reservoir

Identifiers

PMID31447850
PMCPMC6691121
OpenAlexW2963396123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.